| Market Capitalization (Millions $) |
38 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
108 |
| Revenues (TTM) (Millions $) |
69 |
| Net Income (TTM) (Millions $) |
7 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Precision Biosciences Inc
Precision Biosciences Inc. is a biotechnology company founded in 2006 with headquarters in Durham, North Carolina. The company is focused on developing genome editing technologies that enable the precise modification of genes. Precision Biosciences utilizes its proprietary ARCUS Genome Editing technology, which is based on a naturally occurring enzyme called the homing endonuclease I-CreI. This technology allows for modifications in a wide range of cell types, including difficult-to-edit cells such as stem cells.
The company primarily aims to address genetic disorders and improve the development of cell and gene therapies. Precision Biosciences has collaborations with multiple pharmaceutical and biotechnology companies to develop and commercialize therapeutic products based on its genome editing platform. The company's lead product candidate, PBCAR0191, is a CD19-targeted CAR T-cell therapy being developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL).
Precision Biosciences also has a diverse pipeline of other genome editing programs targeting various diseases, including genetic diseases, cancer, and infectious diseases. The company has established partnerships with other companies in the field to leverage its genome editing technology for agricultural applications and sustainable food production.
In summary, Precision Biosciences Inc. is a biotechnology company working on developing precise and versatile genome editing technologies to address genetic disorders, improve cell and gene therapies, and explore other applications in agriculture and food production.
Company Address: 302 East Pettigrew St. Durham 27701 NC
Company Phone Number: 314-5512 Stock Exchange / Ticker: NASDAQ DTIL
|
5.56%